The World Market for Prescription Gastrointestinal Drugs

Questions: Discounts, Updates etc.

Pages: 240

Price (Single): $3,500.00

Price (Company): $7,000.00

Publication Date: 2006-07-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders.

For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description of products on the market, products in research and development, and market estimates and forecasts through 2010 by drug type and by geographical market (U.S. and non-U.S). Competitive market share information is also provided for 2005 and projected for 2010now and and top drugs. The analysis includes market projections for:

In addition to market data, the report includes current issues and trends affecting the industry and what trends may arise in the future and profiles the top competitors in the field.

The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information—specifically revenue and market share data—presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Table of Contents

Chapter One: Executive Summary

Chapter Two: Introduction

Chapter Three: Antiemetics

Chapter Four: Heartburn, GERD, Ulcer Agents

  • Description of Products
    • Histamine H2-Receptor Antagonists
    • Proton Pump Inhibitors
  • Research and Development
  • Market Size and Growth
    • World Market
    • U.S. Market
  • Competitive Analysis

    Chapter Five: Gastrointestinal Cancer Agents

    • Overview
      • Gastrointestinal Conditions
      • Colorectal Cancer
      • Esophageal Cancer
      • Stomach Cancer
      • Prevalence and Incidence
    • Description of Products
    • Research and Development
      • Awaiting Approval and Phase III
      • Other Phase Trials
    • Market Size and Growth
    • World Market
    • U.S. Market
    • Competitive Analysis

    Chapter Six: Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments

    • Overview
      • Conditions
      • Crohn’s Disease and Ulcerative Colitis
      • Diverticular Disease
      • Irritable Bowel Syndrome
      • Prevalence and Incidence
    • Description of Products
    • Research and Development
      • Awaiting Approval and Phase III
      • Other Phase Trials
    • Market Size and Growth
      • World Market
      • U.S. Market
      • Competitive Analysis

    Chapter Seven: Other Gastrointestinal Drugs

    • Overview
      • Conditions
      • Celiac Disease
      • Short Bowel Syndrome
      • Constipation
      • Diarrhea
      • Intestinal Obstruction
      • Digestive Enzyme Disorders
      • Prevalence and Incidence
    • Description of Products
    • Research and Development
      • Awaiting Approval and Phase III
      • Other Product Development Stages
    • Market Size and Growth
      • World Market
      • U.S. Market
    • Competitive Analysis

    Chapter Eight: Issues and Trends

    • Patent Expiration Tactics
    • Rx-to-OTC
    • PillCam ESO
    • Virtual Colonoscopy
    • Insurance Coverage Issues
    • Smoking and Crohn’s Disease
    • Smoking and Ulcerative Colitis
    • Dark Chocolate and Diarrhea

    Chapter Nine: Total Market Size and Forecast

    • Overview
    • Total Market Size and Forecast
    • Markets by Segments
    • Competitor Analysis

    Chapter Ten: Corporate Profiles

    • Introduction
    • Altana Pharma AG
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Axcan Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Centocor, Inc.
    • Eisai, Inc.
    • Genentech, Inc.
    • GlaxoSmithKline plc
    • Janssen L.P.
    • Merck & Company, Inc.
    • Novartis International AG
    • Pfizer, Inc.
    • Procter and Gamble
    • Roche Group
    • Salix Pharmaceuticals, Inc.
    • Sanofi-Aventis
    • Solvay SA
    • Takeda Chemical Industries, Ltd.
    • TAP Pharmaceutical Products, Inc.
    • Wyeth

    Appendix: Company Directory

     

    List of Exhibits

     

    Chapter One: Executive Summary

    • Figure 1-1: Market Summary: World Market Prescription GastrointestinalDrugs 2003-2010
    • Table 1-1: Leading Suppliers Significant Segments of Participation, 2005

    Chapter Three: Antiemetics

  • Table 3-1: Estimated U.S. and World Incidence of Nausea and Vomiting byCause (Chemotherapy and Infectious Disease)
  • Table 3-2: Currently Available Prescription Antiemetic Agents (Brand Name, Generic Name, Manufacturer, Class)
  • Table 3-3: Antiemetics in Development (Product, Developer, Phase, Indication, Projected Approval Date)
  • Table 3-4: World Market for Prescription Antiemetics 2003-2010
  • Table 3-5: World Market for Prescription Antiemetics (U.S. Revenues vsNon-U.S. Revenues) 2003-2010
  • Table 3-6: Market for Prescription Antiemetics Leading Suppliers’ Revenuesand Market Share 2005 and Projected 2010

    Chapter Four: Heartburn, GERD, Ulcer Agents

    • Table 4-1: Estimated World and U.S. Incidence of Heartburn/Indigestion (Daily vs Monthly) and Diagnosed GERD
    • Table 4-2: Currently Available Prescription Antacid Agents (Brand Name,Generic Name, Manufacturer, Class)
    • Table 4-3: Antacids/Antiulcer Agents in Research and Development(Product, Developer, Development Phase, Indication, ProjectedApproval Date)
    • Table 4-4: World Market for Prescription Antacids/Antiulcer Agents2003-2010
    • Table 4-5: World Market Prescription Antacid/Antiulcer Agents by ProductType (H2-Antagonists, Proton Pump Inhibitors, Others) 2003-2010
    • Table 4-6: World Market for Prescription Antacids/Antiulcer Agents (U.S.Revenues vs Non-U.S. Revenues) 2003-2010
    • Table 4-7: Market for Prescription Antacids/Antiulcer Agents Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
    • Table 4-8: Prescription Antacid/Antiulcer Agents Estimated Revenues andMarket Share by Leading Drug 2005

    Chapter Five: Gastrointestinal Cancer Agents

    • Table 5-1: Estimated U.S. and World Incidence and Mortality ofGastrointestinal Cancers by Type
    • Table 5-2: Currently Available Gastrointestinal Cancer Drugs (Brand Name,Generic Name, Manufacturer, Indication)
    • Table 5-3: GI Cancer Agents in Research and Development (Product,Developer, Phase, Class, Indication, Projected Approval Date)
    • Table 5-4: World Market for Gastrointestinal Cancer Drugs 2003-2010
    • Table 5-5: World Market for Gastrointestinal Cancer Drugs by Product Type (Immunotherapy vs Chemotherapy) 2003-2010
    • Table 5-6: World Market for Gastrointestinal Cancer Drugs (U.S. Revenues vsNon-U.S. Revenues) 2003-2010
    • Table 5-7: Market for Gastrointestinal Cancer Drugs Leading Suppliers’Revenues and Market Share 2005 and Projected 2010
    • Table 5-8: Prescription Antacid/Antiulcer Agents Estimated Revenues andMarket Share by Leading Drug 2005

    Chapter Six: Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments

    • Table 6-1: Estimated World and U.S. Prevalence of Crohn’s Disease, IrritableBowel Syndrome, and Related Conditions
    • Table 6-2: Currently Available Prescription Drugs for Crohn’s, IBS, Ulcerative Colitis, and Related Conditions (Brand Name, Generic Name, Manufacturer, Indication)
    • Table 6-3: Antacids/Antiulcer Agents in Research and Development (Product, Developer, Development Phase, Class of Drug, Indication, Projected Approval Date)
    • Table 6-4: World Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments 2003-2010
    • Table 6-5: World Market Prescription Crohn’s Disease, Irritable BowelSyndrome, and Ulcerative Colitis Treatments by Product Type (Anti-inflammatories, Antispasmodics, Others) 2003-2010
    • Table 6-6: World Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments (U.S. Revenues vsNon-U.S. Revenues) 2003-2010
    • Table 6-7: Market for Prescription Crohn’s Disease, Irritable Bowel Syndrome,and Ulcerative Colitis Treatments Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010
    • Table 6-8: Prescription Crohn’s Disease, Irritable Bowel Syndrome, andUlcerative Colitis Treatments: Estimated Revenues and MarketShare by Leading Drug 2005

    Chapter Seven: Other Gastrointestinal Drugs

    • Table 7-1: Estimated World and U.S. Incidence of Other GI Conditions (Diarrhia, Giardiasis, Opioid-Induced Constipation, Digestive EnzymeDisortders)
    • Table 7-2: Currently Available Prescription Products to Treat Other GI Conditions (Brand Name, Generic Name, Manufacturer, Indication)
    • Table 7-3: Other GI Agents in Research and Development (Product, Developer, Development Phase, Drug Class, Indication, Projected ApprovalDate)
    • Table 7-4: World Market for Other Prescription GI Drugs 2003-2010
    • Table 7-5: World Market for Other Prescription GI Drugs by Product Type (Anti-Infectives, Enzymes, Others) 2003-2010
    • Table 7-6: World Market for Other Prescription GI Drugs (U.S. Revenues vsNon-U.S. Revenues) 2003-2010
    • Table 7-7: Market for Prescription Antacids/Antiulcer Agents Leading Suppliers’ Revenues and Market Share 2005 and Projected 2010

    Chapter Eight: Issues and Trends

    • Table 8-1: Prominent Gastrointestinal Drug Patent Expirations through 2010

    Chapter Nine: Total Market Size and Forecast

    • Table 9-1: World Market for Prescription Gastronintestinal Drugs 2003-2010
    • Table 9-2: World Market Prescription Gastrointestinal Drugs by Product Type, 2003-2010
    • Figure 9-1: Trending in the World Market for Prescription GastrointestinalDrugs by Product Type 2003-2010
    • Figure 9-2: World Market Prescription Gastrointestinal Drugs by Percent and Product Type, 2005Table 9-3: Prescription Gastrointestinal Drugs: Leading Suppliers’ Significant Segments of Participation, 2005

     

    • Other users found this report page using the following search terms: gastrointestinal nausea vomiting heartburn gastro-esophageal reflux disease GERD ulcer colorectal cancer esophageal cancer gastric cancer Crohn’s disease ulcerative colitis IBD inflammatory bowel disease irritable bowel syndrome IBS diverticular disease constipation celiac disease short bowel syndrome diarrhea intestinal obstruction prescription market antacid disease size inflammatory prescriptionantacids cancer crohn esophageal

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.